participants meeting any of the following exclusion criteria will not be allowed to participate in this study: 1.history of previous covid-19 infection; 2.positive result for rt-pcr test in the screening period or specific antibody igg or igm meet the following criteria: 1. if igg is positive, the participant will be excluded regardless of the results of other indexes. 2. if igg is negative and igm is positive, it will be determined whether or not to enroll such participant after the result of rt-pcr test is obtained; 3. if both igg and igm are negative, the participant can be vaccinated without waiting for the rt-pcr test results. 3.history of severe acute respiratory syndrome (sars), middle east respiratory syndrome (mers), and other human coronavirus infections or diseases; 4.history of severe allergy to any vaccine, e.g., acute allergic reactions, urticaria, skin eczema, dyspnea, angioneurotic edema or abdominal pain etc., or be allergic to any components of v-01; 5.any confirmed or suspected immunosuppression or immunodeficiency condition known from medical history, including human immunodeficiency virus (hiv) infection, asplenia; 6.serious or uncontrolled cardiovascular diseases, nervous system disorders (e.g., guillain-barre syndrome), blood and lymphatic system disorders, immune system disorders, hepatorenal disorders, respiratory system disorders (e.g., active tuberculosis, pulmonary fibrosis), metabolic and skeletal systems disorders or malignant tumors (except for skin basal cell carcinoma or in situ carcinoma of uterine cervix that has been cured for more than 5 years); 7.hereditary hemorrhagic tendency or coagulation dysfunction, or a history of thrombosis or hemorrhagic disease, or requirement of continuous use of anticoagulants; 8.prior use of any medications to prevent covid-19, e.g., use of antipyretics without pyrexia and any other symptoms; 9.a history of vaccination against sars-cov-2 (marketed or investigational); 10.received attenuated live vaccine within 28 days before the first vaccination or any other vaccines (licensed or investigational) within 14 days before the first vaccination; 11.injection of immunoglobulin and/or other blood products within 3 months before the administration of study vaccine; 12.long-term use (continuous use \>14 days) of glucocorticoids (≥10mg/day of prednisone or its equivalent dose) or other immunosuppressive agents; however, enrollment is allowed for the following conditions: inhaled or topical use of topical steroids, or short-term use (treatment course ≤14 days) of oral steroids; 13.pregnant or breastfeeding women; 14.planning to donate blood during the study period; 15.suspected or known alcohol or drug dependence; 16.history of severe psychiatric disorders which may affect study participation; 17.planning to permanently move from the local area before study completion or leave the local area for a long time during the period of study visits, so that the scheduled visits cannot be followed; 18.those considered by the investigator as inappropriate to participate in the study.

participants meeting any of the following exclusion criteria will not be allowed to participate in this study: 1.history of previous covid-19 infection; 2.positive result for rt-pcr test in the screening period or specific antibody igg or igm meet the following criteria: 1. if igg is positive, the participant will be excluded regardless of the results of other indexes. 2. if igg is negative and igm is positive, it will be determined whether or not to enroll such participant after the result of rt-pcr test is obtained; 3. if both igg and igm are negative, the participant can be vaccinated without waiting for the rt-pcr test results. 3.history of severe acute respiratory syndrome (sars), middle east respiratory syndrome (mers), and other human coronavirus infections or diseases; 4.history of severe allergy to any vaccine, e.g., acute allergic reactions, urticaria, skin eczema, dyspnea, angioneurotic edema or abdominal pain etc., or be allergic to any components of v-01; 5.any confirmed or suspected immunosuppression or immunodeficiency condition known from medical history, including human immunodeficiency virus (hiv) infection, asplenia; 6.serious or uncontrolled cardiovascular diseases, nervous system disorders (e.g., guillain-barre syndrome), blood and lymphatic system disorders, immune system disorders, hepatorenal disorders, respiratory system disorders (e.g., active tuberculosis, pulmonary fibrosis), metabolic and skeletal systems disorders or malignant tumors (except for skin basal cell carcinoma or in situ carcinoma of uterine cervix that has been cured for more than 5 years); 7.hereditary hemorrhagic tendency or coagulation dysfunction, or a history of thrombosis or hemorrhagic disease, or requirement of continuous use of anticoagulants; 8.prior use of any medications to prevent covid-19, e.g., use of antipyretics without pyrexia and any other symptoms; 9.a history of vaccination against sars-cov-2 (marketed or investigational); 10.received attenuated live vaccine within 28 days before the first vaccination or any other vaccines (licensed or investigational) within 14 days before the first vaccination; 11.injection of immunoglobulin and/or other blood products within 3 months before the administration of study vaccine; 12.long-term use (continuous use \>14 days) of glucocorticoids (≥10mg/day of prednisone or its equivalent dose) or other immunosuppressive agents; however, enrollment is allowed for the following conditions: inhaled or topical use of topical steroids, or short-term use (treatment course ≤14 days) of oral steroids; 13.pregnant or breastfeeding women; 14.planning to donate blood during the study period; 15.suspected or known alcohol or drug dependence; 16.history of severe psychiatric disorders which may affect study participation; 17.planning to permanently move from the local area before study completion or leave the local area for a long time during the period of study visits, so that the scheduled visits cannot be followed; 18.those considered by the investigator as inappropriate to participate in the study.

participants meeting any of the following exclusion criteria will not be allowed to participate in this study: 1.history of previous covid-19 infection; 2.positive result for rt-pcr test in the screening period or specific antibody igg or igm meet the following criteria: if igg is positive, the participant will be excluded regardless of the results of other indexes. if igg is negative and igm is positive, it will be determined whether or not to enroll such participant after the result of rt-pcr test is obtained; if both igg and igm are negative, the participant can be vaccinated without waiting for the rt-pcr test results. 3.history of severe acute respiratory syndrome (sars), middle east respiratory syndrome (mers), and other human coronavirus infections or diseases; 4.history of severe allergy to any vaccine, e.g., acute allergic reactions, urticaria, skin eczema, dyspnea, angioneurotic edema or abdominal pain etc., or be allergic to any components of v-01; 5.any confirmed or suspected immunosuppression or immunodeficiency condition known from medical history, including human immunodeficiency virus (hiv) infection, asplenia; 6.serious or uncontrolled cardiovascular diseases, nervous system disorders (e.g., guillain-barre syndrome), blood and lymphatic system disorders, immune system disorders, hepatorenal disorders, respiratory system disorders (e.g., active tuberculosis, pulmonary fibrosis), metabolic and skeletal systems disorders or malignant tumors (except for skin basal cell carcinoma or in situ carcinoma of uterine cervix that has been cured for more than 5 years); 7.hereditary hemorrhagic tendency or coagulation dysfunction, or a history of thrombosis or hemorrhagic disease, or requirement of continuous use of anticoagulants; 8.prior use of any medications to prevent covid-19, e.g., use of antipyretics without pyrexia and any other symptoms; 9.a history of vaccination against sars-cov-2 (marketed or investigational); 10.received attenuated live vaccine within 28 days before the first vaccination or any other vaccines (licensed or investigational) within 14 days before the first vaccination; 11.injection of immunoglobulin and/or other blood products within 3 months before the administration of study vaccine; 12.long-term use (continuous use >14 days) of glucocorticoids (≥10mg/day of prednisone or its equivalent dose) or other immunosuppressive agents; however, enrollment is allowed for the following conditions: inhaled or topical use of topical steroids, or short-term use (treatment course ≤14 days) of oral steroids; 13.pregnant or breastfeeding women; 14.planning to donate blood during the study period; 15.suspected or known alcohol or drug dependence; 16.history of severe psychiatric disorders which may affect study participation; 17.planning to permanently move from the local area before study completion or leave the local area for a long time during the period of study visits, so that the scheduled visits cannot be followed; 18.those considered by the investigator as inappropriate to participate in the study.

participants meeting any of the following exclusion criteria will not be allowed to participate in this study: 1.history of previous covid-19 infection; 2.positive result for rt-pcr test in the screening period or specific antibody igg or igm meet the following criteria: if igg is positive, the participant will be excluded regardless of the results of other indexes. if igg is negative and igm is positive, it will be determined whether or not to enroll such participant after the result of rt-pcr test is obtained; if both igg and igm are negative, the participant can be vaccinated without waiting for the rt-pcr test results. 3.history of severe acute respiratory syndrome (sars), middle east respiratory syndrome (mers), and other human coronavirus infections or diseases; 4.history of severe allergy to any vaccine, e.g., acute allergic reactions, urticaria, skin eczema, dyspnea, angioneurotic edema or abdominal pain etc., or be allergic to any components of v-01; 5.any confirmed or suspected immunosuppression or immunodeficiency condition known from medical history, including human immunodeficiency virus (hiv) infection, asplenia; 6.serious or uncontrolled cardiovascular diseases, nervous system disorders (e.g., guillain-barre syndrome), blood and lymphatic system disorders, immune system disorders, hepatorenal disorders, respiratory system disorders (e.g., active tuberculosis, pulmonary fibrosis), metabolic and skeletal systems disorders or malignant tumors (except for skin basal cell carcinoma or in situ carcinoma of uterine cervix that has been cured for more than 5 years); 7.hereditary hemorrhagic tendency or coagulation dysfunction, or a history of thrombosis or hemorrhagic disease, or requirement of continuous use of anticoagulants; 8.prior use of any medications to prevent covid-19, e.g., use of antipyretics without pyrexia and any other symptoms; 9.a history of vaccination against sars-cov-2 (marketed or investigational); 10.received attenuated live vaccine within 28 days before the first vaccination or any other vaccines (licensed or investigational) within 14 days before the first vaccination; 11.injection of immunoglobulin and/or other blood products within 3 months before the administration of study vaccine; 12.long-term use (continuous use >14 days) of glucocorticoids (≥10mg/day of prednisone or its equivalent dose) or other immunosuppressive agents; however, enrollment is allowed for the following conditions: inhaled or topical use of topical steroids, or short-term use (treatment course ≤14 days) of oral steroids; 13.pregnant or breastfeeding women; 14.planning to donate blood during the study period; 15.suspected or known alcohol or drug dependence; 16.history of severe psychiatric disorders which may affect study participation; 17.planning to permanently move from the local area before study completion or leave the local area for a long time during the period of study visits, so that the scheduled visits cannot be followed; 18.those considered by the investigator as inappropriate to participate in the study.

participants meeting any of the following exclusion criteria will not be allowed to participate in this study: 1.history of previous covid-19 infection; 2.positive result for rt-pcr test in the screening period or specific antibody igg or igm meet the following criteria: 1. if igg is positive, the participant will be excluded regardless of the results of other indexes. 2. if igg is negative and igm is positive, it will be determined whether or not to enroll such participant after the result of rt-pcr test is obtained; 3. if both igg and igm are negative, the participant can be vaccinated without waiting for the rt-pcr test results. 3.history of severe acute respiratory syndrome (sars), middle east respiratory syndrome (mers), and other human coronavirus infections or diseases; 4.history of severe allergy to any vaccine, e.g., acute allergic reactions, urticaria, skin eczema, dyspnea, angioneurotic edema or abdominal pain etc., or be allergic to any components of v-01; 5.any confirmed or suspected immunosuppression or immunodeficiency condition known from medical history, including human immunodeficiency virus (hiv) infection, asplenia; 6.serious or uncontrolled cardiovascular diseases, nervous system disorders (e.g., guillain-barre syndrome), blood and lymphatic system disorders, immune system disorders, hepatorenal disorders, respiratory system disorders (e.g., active tuberculosis, pulmonary fibrosis), metabolic and skeletal systems disorders or malignant tumors (except for skin basal cell carcinoma or in situ carcinoma of uterine cervix that has been cured for more than 5 years); 7.hereditary hemorrhagic tendency or coagulation dysfunction, or a history of thrombosis or hemorrhagic disease, or requirement of continuous use of anticoagulants; 8.prior use of any medications to prevent covid-19, e.g., use of antipyretics without pyrexia and any other symptoms; 9.a history of vaccination against sars-cov-2 (marketed or investigational); 10.received attenuated live vaccine within 28 days before the first vaccination or any other vaccines (licensed or investigational) within 14 days before the first vaccination; 11.injection of immunoglobulin and/or other blood products within 3 months before the administration of study vaccine; 12.long-term use (continuous use >14 days) of glucocorticoids (≥10mg/day of prednisone or its equivalent dose) or other immunosuppressive agents; however, enrollment is allowed for the following conditions: inhaled or topical use of topical steroids, or short-term use (treatment course ≤14 days) of oral steroids; 13.pregnant or breastfeeding women; 14.planning to donate blood during the study period; 15.suspected or known alcohol or drug dependence; 16.history of severe psychiatric disorders which may affect study participation; 17.planning to permanently move from the local area before study completion or leave the local area for a long time during the period of study visits, so that the scheduled visits cannot be followed; 18.those considered by the investigator as inappropriate to participate in the study.

participants meeting any of the following exclusion criteria will not be allowed to participate in this study: 1.history of previous covid-19 infection; 2.positive result for rt-pcr test in the screening period or specific antibody igg or igm meet the following criteria: 1. if igg is positive, the participant will be excluded regardless of the results of other indexes. 2. if igg is negative and igm is positive, it will be determined whether or not to enroll such participant after the result of rt-pcr test is obtained; 3. if both igg and igm are negative, the participant can be vaccinated without waiting for the rt-pcr test results. 3.history of severe acute respiratory syndrome (sars), middle east respiratory syndrome (mers), and other human coronavirus infections or diseases; 4.history of severe allergy to any vaccine, e.g., acute allergic reactions, urticaria, skin eczema, dyspnea, angioneurotic edema or abdominal pain etc., or be allergic to any components of v-01; 5.any confirmed or suspected immunosuppression or immunodeficiency condition known from medical history, including human immunodeficiency virus (hiv) infection, asplenia; 6.serious or uncontrolled cardiovascular diseases, nervous system disorders (e.g., guillain-barre syndrome), blood and lymphatic system disorders, immune system disorders, hepatorenal disorders, respiratory system disorders (e.g., active tuberculosis, pulmonary fibrosis), metabolic and skeletal systems disorders or malignant tumors (except for skin basal cell carcinoma or in situ carcinoma of uterine cervix that has been cured for more than 5 years); 7.hereditary hemorrhagic tendency or coagulation dysfunction, or a history of thrombosis or hemorrhagic disease, or requirement of continuous use of anticoagulants; 8.prior use of any medications to prevent covid-19, e.g., use of antipyretics without pyrexia and any other symptoms; 9.a history of vaccination against sars-cov-2 (marketed or investigational); 10.received attenuated live vaccine within 28 days before the first vaccination or any other vaccines (licensed or investigational) within 14 days before the first vaccination; 11.injection of immunoglobulin and/or other blood products within 3 months before the administration of study vaccine; 12.long-term use (continuous use >14 days) of glucocorticoids (≥10mg/day of prednisone or its equivalent dose) or other immunosuppressive agents; however, enrollment is allowed for the following conditions: inhaled or topical use of topical steroids, or short-term use (treatment course ≤14 days) of oral steroids; 13.pregnant or breastfeeding women; 14.planning to donate blood during the study period; 15.suspected or known alcohol or drug dependence; 16.history of severe psychiatric disorders which may affect study participation; 17.planning to permanently move from the local area before study completion or leave the local area for a long time during the period of study visits, so that the scheduled visits cannot be followed; 18.those considered by the investigator as inappropriate to participate in the study.